Xenon Pharmaceuticals (XENE) Common Equity (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Common Equity data on file, last reported at $1.3 billion in Q1 2026.

• Common Equity for Q1 2026 came in at $1.3 billion, up 90.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 90.04% YoY), and the FY2025 annual result was $581.8 million, down 22.94% from the prior year.
• Common Equity rose to $1.3 billion in Q1 2026 per XENE's latest filing, from $581.8 million in the prior quarter.
• Over five years, Common Equity peaked at $1.3 billion in Q1 2026 and troughed at $541.9 million in Q1 2022.
• A 5-year average of $753.0 million and a median of $721.5 million in 2022 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2025: Common Equity soared 205.78% in 2022, then declined 29.87% in 2025.
• A 5-year view of Common Equity shows it stood at $721.5 million in 2022, then grew by 28.61% to $927.9 million in 2023, then fell by 18.65% to $754.9 million in 2024, then slipped by 22.94% to $581.8 million in 2025, then soared by 129.96% to $1.3 billion in 2026.
• Business Quant data shows XENE's Common Equity at $1.3 billion in Q1 2026, $581.8 million in Q4 2025, and $559.5 million in Q3 2025.